Patients
5.6 % of adults
Diabetes (adults), Kenya, 2022 (WHO).
Compare every country on the Public Health Dashboard
Updated
Reviewed by Chandani Patel
Kenya Insulin Delivery Devices Market Analysis Industry Trends and Forecast to 2034: Segmented by (By Product Type, By Distribution Channel, By Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$12.0 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $11.9 Mn | — | — |
| 2025 (base) | $12.9 Mn | +$0.9 Mn | — |
| 2026 (forecast) | $13.8 Mn | +$1.0 Mn | +7.6% |
| 2027 (forecast) | $14.9 Mn | +$1.1 Mn | +15.8% |
| 2028 (forecast) | $16.0 Mn | +$1.1 Mn | +24.6% |
| 2029 (forecast) | $17.2 Mn | +$1.2 Mn | +34% |
| 2030 (forecast) | $18.5 Mn | +$1.3 Mn | +44.2% |
| 2031 (forecast) | $19.9 Mn | +$1.4 Mn | +55.2% |
| 2032 (forecast) | $21.5 Mn | +$1.5 Mn | +67% |
| 2033 (forecast) | $23.1 Mn | +$1.6 Mn | +79.7% |
| 2034 (forecast) | $24.8 Mn | +$1.8 Mn | +93.3% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $12.9 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $24.8 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 7.6% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Product type and distribution channel (see all) |
| Key players | Novo Nordisk A/S, Medtronic, Sanofi, Abbott Laboratories, Eli Lilly and Company and 1 more (see all) |
| Regulator in Kenya | PPBSource: Pharmacy and Poisons Board. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Diabetes is a disease that requires careful administration of Insulin through Insulin delivery devices to maintain blood sugar levels. These are insulin pens (reusable and disposable), that can administer a continuous supply of insulin through a catheter known as insulin pump, syringe injections, and jet injectors which are needleless. Other creative possibilities are inhalers and patches. These devices assist patients to regulate blood glucose levels, convenience and advance diabetes self-management with facilities such as programmable dosage and tracking. The IDF Diabetes Atlas (2021) reports that 10.5% of the adult population (20-79 years) has diabetes, with almost half unaware that they are living with the condition.
The global market for insulin delivery devices is expanding at a fairly constant rate due to increasing rates of diabetes, innovative technologies, and high consumer demand for improved insulin administration essentials. Leading vendors include Medtronic, Novo Nordisk, and Eli Lilly, while regions such as North America and Asia-Pacific exhibit the highest level of technology maturity. Some of the challenges include high costs, stringent regulations, and competition from other diabetes oral tablets. Future trends in innovation include the use of artificial intelligence, wearable technology, and biosimilar medication that is cheaper and accessible to the population.
The increasing incidence of diabetes, influenced by urban development, an aging demographic, and shifts in lifestyle, serves as a significant catalyst, with a growing population of elderly and overweight individuals necessitating insulin therapy. Technological innovations, including intelligent insulin delivery systems and continuous glucose monitoring tools, significantly improve diabetes management, while advantageous reimbursement frameworks and escalating healthcare investments in developing regions further bolster market expansion.
Innovations in artificial pancreas systems (APS) are poised to enhance precision and ease of use, thereby improving glycemic control. Cutting-edge delivery modalities such as transdermal patches and inhalable insulin are anticipated to offer non-invasive and less frequent administration alternatives. The incorporation of digital health technologies, encompassing mobile applications and data analytics, will facilitate a more customized and proactive approach to diabetes management. Furthermore, the expansion of healthcare infrastructure and increased awareness in emerging markets, particularly in Asia and Africa, create opportunities for affordable insulin solutions.
The elevated expenses associated with advanced medical devices, such as insulin pumps and smart pens, hinder their adoption, particularly in developing nations with constrained healthcare budgets. Product recalls and safety apprehensions, including cybersecurity vulnerabilities related to connected devices, can undermine consumer confidence and impede market growth. Practical challenges, such as the size and discomfort of certain devices, further restrict patient acceptance. Moreover, rigorous regulatory standards may postpone the launch of innovative products, thereby decelerating market expansion.
August 2024, FDA Clears First Device to Enable Automated Insulin Dosing for Individuals with Type 2 Diabetes. Agency Supports Broader Access to Innovative Technology in Diabetes Management.
February 2024, Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, announced the United States commercial launch of its new Tandem Mobi, the world’s smallest, durable automated insulin delivery system for people living with diabetes.
June 2024, Insulet Corporation has announced that its Omnipod 5, a tubeless automated insulin delivery system compatible with Dexcom G6 and Abbott FreeStyle Libre 2 Plus continuous glucose monitors, is fully available in the U.K. and the Netherlands. This marks the first AID system integrated with both leading CGM brands and is approved for use by individuals aged two years and older with type 1 diabetes.
June 2024, CeQur Simplicity™, a Wearable Mealtime Insulin Delivery Device, Obtains FDA-Clearance for 4 Days of Wear to Further Simplify Diabetes Management.
May 2025, FDA Cleared New Insulin Pump and Algorithm-Based Software to Support Enhanced Automatic Insulin Delivery. Agency Continues to Support Innovation of Next-Generation Technology in Diabetes Management.
February 2024, Catalent was recently acquired by Novo Holdings for $16.5 billion. This deal was slated to close later in 2024. As part of the deal, Novo Nordisk has agreed to acquire three fill-finish sites from Novo Holdings for $11 billion—the sites are in Italy, Belgium, and Bloomington, IN, in the U.S.
May 2025, Medtronic plc announced its acquisition of EOFlow Co. Ltd., the manufacturer of the EOPatch®, a tubeless, wearable, and fully disposable insulin delivery device. This acquisition, combined with Medtronic's Meal Detection Technology™ algorithm and next-generation continuous glucose monitor (CGM), is expected to enhance Medtronic's ability to meet the diverse needs of individuals with diabetes, regardless of their treatment preferences or stage in their diabetes management journey.
The Pharmacy and Poisons Board (PPB) registers medical devices as well as medicines.[1] The Social Health Authority (SHA) replaced the National Health Insurance Fund (NHIF) in October 2024.[2] Diabetes (adults): 5.6% of adults in 2022, the latest WHO figure for Kenya.[3]
[1] Pharmacy and Poisons Board. Checked 14 Nov 2026.
[2] Social Health Authority. Checked 14 Nov 2026.
[3] WHO Global Health Observatory, Diabetes (adults, WHO) (% of adults). Retrieved 15 Nov 2026.
Numerous nations, especially in North America, possess comprehensive reimbursement policies that facilitate patient access to advanced diabetes management solutions. Nonetheless, coverage may vary, with developed markets typically providing extensive support while developing regions encounter challenges. Emerging markets such as India and China are anticipated to experience advancements in reimbursement as their healthcare systems evolve. Furthermore, policy modifications are influencing the market, with an increasing emphasis on preventive care, enhanced support for telehealth, and expedited regulatory approval processes improving access to and adoption of novel technologies.
What doctors and scientists are doing in Insulin Delivery Devices right now, from free public sources.
5.6 % of adults
Diabetes (adults), Kenya, 2022 (WHO).
Compare every country on the Public Health DashboardSources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] WHO Global Health Observatory, Diabetes (adults, WHO) (% of adults). Retrieved 17 Nov 2026.
[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.
[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 17 Nov 2026.
From our blog
Kenya · 4 shared keywords
Kenya · 4 shared keywords
Kenya · 2 shared keywords
Kenya · 2 shared keywords
Kenya · 2 shared keywords
Kenya · 1 shared keyword
Pharmaceuticals · Kenya
Healthcare Services · Kenya
Digital Health · Kenya
Pharmaceuticals · Kenya
Pharmaceuticals · Kenya
Healthcare Services · Kenya